-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Jingfang Pharmaceutical-B (02595.HK) announced that the oral Pan-RAS inhibitor GFH276 has entered a Phase IB/II multi-center, open-label combination therapy study, which will be carried out at dozens of Chinese and Australian research centers. The first overseas enlisted patient recently completed administration at Monash Health in Australia. The first case of the Chinese enrolled patient completed administration at Fudan University Oncology Hospital in the third quarter of this year. The study aims to evaluate the efficacy and safety of multiple combination therapies for RAS mutant pancreatic cancer and advanced solid tumors; the phase II trial phase will include three first-line pancreatic cancer treatment cohorts, namely GFH276 combined with cetuximab (EGFR monoclonal antibody), GFH276 combined with AG (standardized treatment plan), and GFH276 combined with mfolfirinox (standardized treatment plan).

Zhitongcaijing·11/16/2026 00:09:02
Listen to the news
Zhitong Finance App News, Jingfang Pharmaceutical-B (02595.HK) announced that the oral Pan-RAS inhibitor GFH276 has entered a Phase IB/II multi-center, open-label combination therapy study, which will be carried out at dozens of Chinese and Australian research centers. The first overseas enlisted patient recently completed administration at Monash Health in Australia. The first case of the Chinese enrolled patient completed administration at Fudan University Oncology Hospital in the third quarter of this year. The study aims to evaluate the efficacy and safety of multiple combination therapies for RAS mutant pancreatic cancer and advanced solid tumors; the phase II trial phase will include three first-line pancreatic cancer treatment cohorts, namely GFH276 combined with cetuximab (EGFR monoclonal antibody), GFH276 combined with AG (standardized treatment plan), and GFH276 combined with mfolfirinox (standardized treatment plan).